Aggressive prostate cancer halted with new treatment

The RADAR (Randomised Androgen Deprivation and Radiotherapy) trial enrolled 1071 men with newly-diagnosed aggressive but localised prostate cancer between 2003 and 2007 from 23 centres across Australia and New Zealand.

All men received six months of testosterone suppression therapy, using leuprorelin, followed by radiotherapy.